secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001493152-25-010138
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus reports Q4 loss per share $1.61; cash $5.8M; Decoy20 trial enrolls >20 patients
--------------------------------------------------------------------------------

- Cash and equivalents $5.8M as of Dec 31, 2024; Jan 2025 private placement raised net $2.0M.
- Entered $20M equity line with Yorkville in Feb 2025; expects cash runway into Q2 2025.
- Phase 1 Decoy20 weekly dosing cohort >20 patients; early stable disease observed.
- R&D expense Q4 2024 $2.5M vs $2.0M YoY; full-year $7.2M vs $7.6M.
- Clinical supply agreement with BeiGene for tislelizumab combo trial expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315225010138/0001493152-25-010138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315225010138/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-010138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer